Ziopharm Prices Secondary Offering
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
[cnxvideo id=”655420″ placement=”ros”]Ziopharm Oncology Inc. (NASDAQ: ZIOP) saw its shares slide early on Friday after the company announced the pricing of its secondary offering. The company priced its 9.71 million shares at $5.15 per share to a single institutional investor. The gross proceeds from the offering are expected to be roughly $50 million.
Guggenheim Securities is acting as the sole underwriter and book-running manager for the offering.
This Massachusetts-based biotechnology company employs novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Ziopharm’s immuno-oncology programs, in collaboration with Intrexon Corp. (NYSE: XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability.
[nativounit]
The company is advancing programs in multiple stages of development together with Intrexon’s RheoSwitch Therapeutic System technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. Ziopharm’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing that are focused on hematologic and solid tumor malignancies.
The company intends to use the net proceeds from the offering for general corporate and working capital purposes, including the advancement of its clinical programs.
Shares of Ziopharm were last seen down 2.5% at $6.94 on Friday, with a consensus analyst price target of $23.00 and a 52-week trading range of $4.45 to $7.99.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
